Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial
Published Oct 26, 2019 · D. Matthews, P. Paldánius, Pieter Proot
The Lancet
208
Citations
10
Influential Citations
Abstract
Abstract removed due to Elsevier request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
Study Snapshot
Key takeawayEarly combination therapy with vildagliptin and metformin is more effective in maintaining glycemic control than sequential metformin monotherapy in newly diagnosed type 2 diabetes patients.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.